|
|
|
|
|
From our three decades of experience in pharma and biotechnology, we learnt to mitigate the risks associated with basic research and difficulties in monetizing such innovations.
|
|
Today our focus is on applied research that brings the Drug and Technology development to a conclusion at the earliest in an effort to commercialize those through strategic partnerships or out-licensing.
TBL's basic rules for selecting and marketing technologies
|
We do not undertake fundamental research such as the development of new molecules. |
|
We consider only those technologies where the drugs of interest have already been developed to a basic degree, and proven at least to the extent of in-vitro efficacy. It is considered a bonus when the drugs have been shown positive results even in minimal animal trials. |
|
We do not enter into retail marketing of any product on our own. For marketing, we employ a two pronged strategy:
» |
We partner with leading companies around the world for our cutting edge technologies, either through out-licensing or other forms of collaboration. |
» |
We seek strategic alliances for our Biogenerics, to market our products either globally or regionally depending on the product and partner. |
|
|
|
|
|
|
|
|
|
|
© 2011. TRANSGENE BIOTEK LIMITED., All Rights Reserved. |
Designed by BitraNet |
|
|
|
|
|